Sucrase

Phase 2Protein / enzyme

UUniversity of Miami

Sucrase is one of 20 small molecule programs targeting Short Bowel Syndrome. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Short Bowel SyndromeActive, not recruiting

Short Bowel SyndromePhase 2

Active, not recruiting

Competition

Competitive Landscape

28 competitors in Short Bowel Syndrome

#DrugCompanyPhaseTrials

Eliquis

Bristol-Myers Squibb

Approved

1 2

Byetta

AstraZeneca

Approved

1 3

Victoza

Growth Hormone

1 5

Ursodeoxycholic Acid

Daewoong Pharmaceutical Co. LTD.

Approved

1 6

Dipeptidyl Peptidase 4 Inhibitor

Boehringer Ingelheim

Approved

1 7

Questran

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 2

1 8

Rhgh

XXiamen Amoytop Biotech Co., Ltd.

Phase 3

1 9

Teduglutide /kg

Takeda

Phase 3

3 10

Apraglutide

VVectivBio AG

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Short Bowel Syndrome1 trial

Functional Sucrase Deficiency in Short Bowel Syndrome Patients With Intestinal Failure

Terminated·UUniversity of Miami·Phase 2·NCT04604275·3 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Sucrase. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Sucrase compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Sucrase. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Miami company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Protein / enzyme[2]
Highest Phase: Phase 2[1]
Company: UUniversity of Miami

Sucrase

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Short Bowel Syndrome1 trial

References

Drug Info

Quick Facts

Related News